Anubhav Mittal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anubhav Mittal has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jaswinder S. Samra
Department of Upper Gastrointestinal Surgery Royal North Shore Hospital St Leonards New South Wales Australia
8 shared publications - Krishna Kotecha
Department of Upper Gastrointestinal Surgery Royal North Shore Hospital St Leonards New South Wales Australia
5 shared publications - Hiro Masuda
Department of Upper Gastrointestinal Surgery Royal North Shore Hospital St Leonards New South Wales Australia
3 shared publications Nick Pavlakis
Sydney Medical School, University of Sydney Sydney New South Wales Australia
3 shared publicationsAnthony J. Gill
Northern Clinical School, Faculty of Medicine & Health University of Sydney Sydney Australia
2 shared publications- Kai Brown
Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Anz Journal of Surgery
Indocyanine Green Fluorescence Cholangiography With Selective Intraoperative Cholangiography: A Proposed Standard for Laparoscopic Cholecystectomy
- 21 October 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessIndocyanine Green Fluorescence Cholangiography With Selective Intraoperative Cholangiography: A Proposed Standard for Laparoscopic Cholecystectomy
- 4 October 2026
- Published by Wiley in Anz Journal of Surgery
Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy
Background: The PANAMA score was developed as a post‐NAT prognostic tool for PDAC. Prior validations have been dominated by pancreatic head cancers. Pancreatic body and tail tumours represent a biologically distinct subgroup and remain underrepresented in NAT cohorts. Whether the score reliably predicts outcomes in distal PDAC remains unknown. Methods: A retrospective study was conducted at a single centre including patients with PDAC who received NAT followed by distal pancreatectomy between January 2015 and December 2024. Patients were stratified into low‐, intermediate‐ and high‐risk groups based on the original PANAMA score. Overall survival (OS) and disease‐free survival (DFS) were assessed. Prognostic performance of the PANAMA score and AJCC staging was compared. Results: Fifty‐two patients were included. Median OS and DFS were 40.8 months (95% CI: 28.7–55.0) and 11.6 months (95% CI: 9.7–14.5), respectively. High‐risk patients showed worse OS compared to intermediate‐ and low‐risk groups (21.8, 31.1 and 55.0 months, respectively, p = 0.009). A similar pattern was observed for DFS (10.3, 11.2 and 29.2 months, respectively, p = 0.029). The AJCC stage outperformed the PANAMA score in OS prediction ( C ‐index 0.70 vs. 0.64). Conclusion: The PANAMA score effectively stratifies patients with pancreatic body and tail PDACs undergoing neoadjuvant therapy and resection into prognostic groups.
- 4 October 2026
- Published by Wiley in Anz Journal of Surgery
Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy
Background: The PANAMA score was developed as a post‐NAT prognostic tool for PDAC. Prior validations have been dominated by pancreatic head cancers. Pancreatic body and tail tumours represent a biologically distinct subgroup and remain underrepresented in NAT cohorts. Whether the score reliably predicts outcomes in distal PDAC remains unknown. Methods: A retrospective study was conducted at a single centre including patients with PDAC who received NAT followed by distal pancreatectomy between January 2015 and December 2024. Patients were stratified into low‐, intermediate‐ and high‐risk groups based on the original PANAMA score. Overall survival (OS) and disease‐free survival (DFS) were assessed. Prognostic performance of the PANAMA score and AJCC staging was compared. Results: Fifty‐two patients were included. Median OS and DFS were 40.8 months (95% CI: 28.7–55.0) and 11.6 months (95% CI: 9.7–14.5), respectively. High‐risk patients showed worse OS compared to intermediate‐ and low‐risk groups (21.8, 31.1 and 55.0 months, respectively, p = 0.009). A similar pattern was observed for DFS (10.3, 11.2 and 29.2 months, respectively, p = 0.029). The AJCC stage outperformed the PANAMA score in OS prediction ( C ‐index 0.70 vs. 0.64). Conclusion: The PANAMA score effectively stratifies patients with pancreatic body and tail PDACs undergoing neoadjuvant therapy and resection into prognostic groups.
- Open Access
- 3 August 2026
- Published by Wiley in Anz Journal of Surgery
How to Do a Laparoscopic Left Hepatectomy for Cystic Lesions Compressing the Middle Hepatic Vein: The Hemodynamic Advantage of Pneumoperitoneum
- 3 August 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessHow to Do a Laparoscopic Left Hepatectomy for Cystic Lesions Compressing the Middle Hepatic Vein: The Hemodynamic Advantage of Pneumoperitoneum
- Open Access
- 14 July 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (9) , 2267-2269
AI and Epigenetics: A New Opportunity for Early Pancreatic Cancer Detection in Australia
- 14 July 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (9) , 2267-2269
Open AccessAI and Epigenetics: A New Opportunity for Early Pancreatic Cancer Detection in Australia
- 24 May 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Use of Interventional Radiologically Guided Covered Self‐Expanding Metallic Stents for the Treatment of Hepaticojejunostomy Leaks
Introduction: To assess the efficacy and safety of interventional radiology‐guided covered self‐expanding metallic stents (CSEMS) in the management of hepaticojejunostomy (HJ) bile leaks following major hepatic and pancreatic resections. Methods: A retrospective study was conducted of all patients who developed HJ bile leaks after hepatic and pancreatic resections between January 2020 and February 2025 at a single tertiary referral centre. Analysis was performed on patients managed with percutaneous, IR‐guided CSEMS placement. Patient demographics, clinical presentation, procedural details, stent characteristics and outcomes were collected. The primary endpoint was successful radiological resolution of the bile leak. Secondary endpoints included procedural complications and 90‐day mortality. Results: Nine patients with HJ leaks were managed with IR‐guided CSEMS placement. The index operation was a pancreaticoduodenectomy in 7 of 9 patients and extended hepatectomy with bile duct reconstruction in 2 of 9 patients. The overall success rate for leak resolution was 100%. The median time to radiological resolution was 21.5 days (range, 7–51 days). Complications occurred in 4 of 9 patients, consisting of stent migration in one patient and cholangitis in three patients. No patient required surgical intervention for the HJ leak. Conclusion: The use of IR‐guided CSEMS for managing HJ bile leaks is a highly effective and minimally invasive treatment. It demonstrates an excellent success rate for leak resolution with a manageable complication profile, representing a reliable alternative to surgical re‐intervention in this complex patient population.
- 24 May 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Use of Interventional Radiologically Guided Covered Self‐Expanding Metallic Stents for the Treatment of Hepaticojejunostomy Leaks
Introduction: To assess the efficacy and safety of interventional radiology‐guided covered self‐expanding metallic stents (CSEMS) in the management of hepaticojejunostomy (HJ) bile leaks following major hepatic and pancreatic resections. Methods: A retrospective study was conducted of all patients who developed HJ bile leaks after hepatic and pancreatic resections between January 2020 and February 2025 at a single tertiary referral centre. Analysis was performed on patients managed with percutaneous, IR‐guided CSEMS placement. Patient demographics, clinical presentation, procedural details, stent characteristics and outcomes were collected. The primary endpoint was successful radiological resolution of the bile leak. Secondary endpoints included procedural complications and 90‐day mortality. Results: Nine patients with HJ leaks were managed with IR‐guided CSEMS placement. The index operation was a pancreaticoduodenectomy in 7 of 9 patients and extended hepatectomy with bile duct reconstruction in 2 of 9 patients. The overall success rate for leak resolution was 100%. The median time to radiological resolution was 21.5 days (range, 7–51 days). Complications occurred in 4 of 9 patients, consisting of stent migration in one patient and cholangitis in three patients. No patient required surgical intervention for the HJ leak. Conclusion: The use of IR‐guided CSEMS for managing HJ bile leaks is a highly effective and minimally invasive treatment. It demonstrates an excellent success rate for leak resolution with a manageable complication profile, representing a reliable alternative to surgical re‐intervention in this complex patient population.
- 8 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (7-8) , 2211-2213
How to Do a Laparoscopic Caudate Lobectomy (With Video)
This paper describes the surgical technique for a laparoscopic caudate lobectomy, offering a detailed educational demonstration of this complex procedure. Our contribution focuses on the clear visualisation of the intricate anatomical relationships with major vascular structures and outlines the key steps to approach this technically challenging operation safely.
- 8 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (7-8) , 2211-2213
How to Do a Laparoscopic Caudate Lobectomy (With Video)
This paper describes the surgical technique for a laparoscopic caudate lobectomy, offering a detailed educational demonstration of this complex procedure. Our contribution focuses on the clear visualisation of the intricate anatomical relationships with major vascular structures and outlines the key steps to approach this technically challenging operation safely.
- 30 March 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 133 (7) , 926-933
Impact of Symptom Phenotype on Surgical Quality and Survival in Small‐Bowel Neuroendocrine Tumours: A Quality Metrics Analysis
Background: There is debate regarding the optimal management of small‐bowel neuroendocrine tumours (SBNETs), particularly concerning upfront resection in various clinical presentations. While symptom phenotypes are known to influence survival, their impact on technical surgical quality, especially in the emergency setting, remains poorly defined. This study evaluates whether symptom phenotype compromises the delivery of guideline‐concordant surgical care. Methods: A retrospective analysis of 108 consecutive SBNET resections (2000–2023) at a specialized tertiary centre was performed. Patients were stratified into four phenotypes: obstructive/perforation ( n = 54), carcinoid syndrome (22), asymptomatic/incidental (22), and other symptoms (9). Operative metrics, including lymph‐node harvest (LNY) and margin status (R0/R1), were compared alongside overall survival (OS). Results: Symptom phenotype was a predictor of operative urgency and approach. Obstructive cases required emergency surgery in 50% of instances compared to ≤ 11% in all other groups ( p < 0.001). Synchronous liver metastases were most prevalent in the carcinoid syndrome phenotype (50%) and lowest in the asymptomatic group (5%) ( p = 0.002). Despite these disparities in presentation and urgency, technical quality markers were uniform across all groups: median LNY ranged from 10 to 13 ( p = 0.426), R1/R2 margin rates were statistically similar ( p = 0.290), and median length of stay was 8 days for all cohorts ( p = 0.311). Multivariable analysis identified the asymptomatic phenotype as independently protective for OS (HR 0.42, p = 0.032), while liver metastasis was the strongest adverse prognostic factor (HR 3.25, p < 0.001). Conclusions: Symptom phenotype dictates operative urgency and reflects disease burden but does not compromise the technical standards of surgery in a specialized unit. These findings suggest that high‐quality, guideline‐concordant lymphadenectomy is achievable even in emergency obstructive presentations, and correspondingly, access to specialized surgical oncology expertise may be sought even in obstructed patients to ensure technical quality is maintained.
- 30 March 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 133 (7) , 926-933
Impact of Symptom Phenotype on Surgical Quality and Survival in Small‐Bowel Neuroendocrine Tumours: A Quality Metrics Analysis
Background: There is debate regarding the optimal management of small‐bowel neuroendocrine tumours (SBNETs), particularly concerning upfront resection in various clinical presentations. While symptom phenotypes are known to influence survival, their impact on technical surgical quality, especially in the emergency setting, remains poorly defined. This study evaluates whether symptom phenotype compromises the delivery of guideline‐concordant surgical care. Methods: A retrospective analysis of 108 consecutive SBNET resections (2000–2023) at a specialized tertiary centre was performed. Patients were stratified into four phenotypes: obstructive/perforation ( n = 54), carcinoid syndrome (22), asymptomatic/incidental (22), and other symptoms (9). Operative metrics, including lymph‐node harvest (LNY) and margin status (R0/R1), were compared alongside overall survival (OS). Results: Symptom phenotype was a predictor of operative urgency and approach. Obstructive cases required emergency surgery in 50% of instances compared to ≤ 11% in all other groups ( p < 0.001). Synchronous liver metastases were most prevalent in the carcinoid syndrome phenotype (50%) and lowest in the asymptomatic group (5%) ( p = 0.002). Despite these disparities in presentation and urgency, technical quality markers were uniform across all groups: median LNY ranged from 10 to 13 ( p = 0.426), R1/R2 margin rates were statistically similar ( p = 0.290), and median length of stay was 8 days for all cohorts ( p = 0.311). Multivariable analysis identified the asymptomatic phenotype as independently protective for OS (HR 0.42, p = 0.032), while liver metastasis was the strongest adverse prognostic factor (HR 3.25, p < 0.001). Conclusions: Symptom phenotype dictates operative urgency and reflects disease burden but does not compromise the technical standards of surgery in a specialized unit. These findings suggest that high‐quality, guideline‐concordant lymphadenectomy is achievable even in emergency obstructive presentations, and correspondingly, access to specialized surgical oncology expertise may be sought even in obstructed patients to ensure technical quality is maintained.
- 28 March 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (5) , 1363-1373
Short‐Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta‐Analysis of Observational Studies
Background: The present study aimed to review and analyze the impact of arterial divestment during pancreatic surgery on short‐term outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched. Outcomes of interest included perioperative parameters, resection margins, morbidity, and mortality. Analysis was performed using the meta package in R. Results: Five observational studies comprising 554 patients were included. Two hundred twelve patients had upfront surgery, and 342 patients had neoadjuvant chemotherapy. Four hundred and eighty‐two had periarterial dissection and 72 sub adventitial dissection. Operative time varied considerably (median 185–537 min), and intraoperative blood loss ranged between 300 and 900 mL. The pooled prevalence of blood transfusion was 37.6% (95% CI: 32.5%–43.1%; I 2 = 97.7%). Median post‐operative stay ranged from 7 to 25 days. R0 resection was achieved in 49.4% (95% CI: 44.9%–53.8%). Complications included post‐operative pancreatic fistula (9.2%), delayed gastric emptying (11.2%), post‐operative pancreatic hemorrhage (5.8%), chyle leakage (13.9%), reoperation (6.1%), 90‐day mortality (3.1%), bile leakage (≤ 2.8%), ischemia (≤ 4.2%), and intractable diarrhea (8%–13%). Conclusions: Arterial divestment during pancreatic surgery appears to have acceptable morbidity and mortality. However, there is a lack of a unified agreed definition and case selection. A unified reporting, standardization of terminology and relative role compared to arterial resection should be explored in prospective studies.
- 28 March 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (5) , 1363-1373
Short‐Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta‐Analysis of Observational Studies
Background: The present study aimed to review and analyze the impact of arterial divestment during pancreatic surgery on short‐term outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched. Outcomes of interest included perioperative parameters, resection margins, morbidity, and mortality. Analysis was performed using the meta package in R. Results: Five observational studies comprising 554 patients were included. Two hundred twelve patients had upfront surgery, and 342 patients had neoadjuvant chemotherapy. Four hundred and eighty‐two had periarterial dissection and 72 sub adventitial dissection. Operative time varied considerably (median 185–537 min), and intraoperative blood loss ranged between 300 and 900 mL. The pooled prevalence of blood transfusion was 37.6% (95% CI: 32.5%–43.1%; I 2 = 97.7%). Median post‐operative stay ranged from 7 to 25 days. R0 resection was achieved in 49.4% (95% CI: 44.9%–53.8%). Complications included post‐operative pancreatic fistula (9.2%), delayed gastric emptying (11.2%), post‐operative pancreatic hemorrhage (5.8%), chyle leakage (13.9%), reoperation (6.1%), 90‐day mortality (3.1%), bile leakage (≤ 2.8%), ischemia (≤ 4.2%), and intractable diarrhea (8%–13%). Conclusions: Arterial divestment during pancreatic surgery appears to have acceptable morbidity and mortality. However, there is a lack of a unified agreed definition and case selection. A unified reporting, standardization of terminology and relative role compared to arterial resection should be explored in prospective studies.
- Open Access
- 20 January 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (3) , 678-680
The Surgeon's Hand: The Most Sensitive Instrument in Detection of Small Bowel Neuroendocrine Tumors
- 20 January 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (3) , 678-680
Open AccessThe Surgeon's Hand: The Most Sensitive Instrument in Detection of Small Bowel Neuroendocrine Tumors